Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio to Predict Carotid Intima-Media Thickness in Chronic Kidney Disease Patients

NCT05472805 | Completed

• 1 other identifier: NLRandPLRtoCIMTinCKD
• Study Type: observational
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to determine whether the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can be used as predictors of coronary heart disease (CHD) in CKD patients undergoing dialysis at Moewardi General Hospital Surakarta. It was hypothesized that NLR and PLR, which have been identified as inflammatory biomarkers, would be significantly related to increased arotid intima-media thickness (CIMT) in CKD patients undergoing dialysis. This study is an observational analytic study using a cross-sectional approach conducted at department of renal-hypertension and hemodialysis unit in Moewardi General Hospital in Surakarta, Indonesia from January to July 2022.

Conditions

Chronic Kidney Diseases; Dialysis; Complications; Coronary Heart Disease

Keywords

neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; carotid intima-media thickness; chronic kidney disease; dialysis

Outcome Measures

Primary Outcomes (2)

• Neutrophil-lymphocyte ratio (NLR)

  The absolute values of neutrophils that divided by the absolute values of lymphocytes

  Only in admission

• Platelet-lymphocyte ratio (PLR)

  The absolute values of platelet that divided by the absolute values of lymphocytes

  Only in admission

Study Arms (2)

CIMT ≥1mm

The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT ≥1mm

CIMT <1mm

The measurement of CIMT will be carried by a cardiologist in the cardiovascular department using B mode ultrasound. The cardiologist will measure both of the carotid artery, and higher measurement of CIMT will be recorded. This group includes individual with CIMT \<1mm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with a diagnosis of CKD stage V on HD or CAPD based RRTs from the department of renal-hypertension and hemodialysis unit in Moewardi General Hospital in Surakarta, Indonesia from January to July 2022.

You may qualify if:

• diagnosis of CKD stage V
• on HD or CAPD based RRTs

You may not qualify if:

• cardiovascular, neoplastic, chronic inflammatory, or infectious disease
• usage of immunosuppressants or antiplatelet drugs

Sponsors & Collaborators

• Universitas Sebelas Maret: lead

Study Sites (1)

RS UNS (Universitas Sebelas Maret Hospital)

Surakarta, Central Java, 57145, Indonesia

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Coronary Disease

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: July 21, 2022
• First Posted: July 25, 2022
• Study Start: January 1, 2022
• Primary Completion: July 1, 2022
• Study Completion: July 1, 2022
• Last Updated: July 25, 2022

Record last verified: 2022-07

Locations

ID (1)